taselisib

Roche dumps its PhIII PI3K effort on taselisib after researchers track poor survival edge, harsh side effects for breast cancer
Endpoints
Sun, 06/3/18 - 10:29 am
Roche
taselisib
fulvestrant
metastatic breast cancer
ASCO 2018
Drug Combination Slows Growth of Most Common Type of Advanced Breast Cancer
Memorial Sloan Kettering Cancer Center
Sat, 06/2/18 - 10:55 pm
ASCO 2018
taselisib
fulvestrant
metastatic breast cancer
estrogen-receptor cancer